Dear Dr. Renukaprasad A R,  Did you know that anaplastic lymphoma kinase (ALK)-positive NSCLC patients can significantly benefit from ALK inhibitors? - ALK rearrangements are often but not exclusively found in lung tumors from relatively young, never, or light smokers with adenocarcinoma. However, all patients with advanced NSCLC should be tested for ALK rearrangements.
- For patients with advanced or metastatic ALK-positive NSCLC, we recommend initial treatment with an ALK inhibitor rather than chemotherapy.
- To gain deeper insights on this topic, click on the post link given below.
Stay updated with UpToDate®, evidence-based clinical decision support. As a verified Docplexus user, you will receive special pricing on personal subscriptions to UpToDate®
Professional verified users: SAVE 15%
Resident verified users: SAVE 20%
*Offer on annual and longer subscriptions only. Prices for Docplexus users are reflected on the UpToDate® storefront when you sign in to the Docplexus App with your user login credentials. Applicable taxes may apply. Proof of status is required for all resident orders. | .png)
No comments:
Post a Comment